Pathogenesis of depression: insights from human and rodent studies

C Ménard, GE Hodes, SJ Russo - Neuroscience, 2016 - Elsevier
Major depressive disorder (MDD) will affect one out of every five people in their lifetime and
is the leading cause of disability worldwide. Nevertheless, mechanisms associated with the …

WNT signaling in cardiac and vascular disease

S Foulquier, EP Daskalopoulos, G Lluri… - Pharmacological …, 2018 - Elsevier
WNT signaling is an elaborate and complex collection of signal transduction pathways
mediated by multiple signaling molecules. WNT signaling is critically important for …

GSK-3β, a pivotal kinase in Alzheimer disease

M Llorens-Marítin, J Jurado, F Hernández… - Frontiers in molecular …, 2014 - frontiersin.org
Alzheimer disease (AD) is the most common form of age-related dementia. The etiology of
AD is considered to be multifactorial as only a negligible percentage of cases have a familial …

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics

RS Jope, CJ Yuskaitis, E Beurel - Neurochemical research, 2007 - Springer
Deciphering what governs inflammation and its effects on tissues is vital for understanding
many pathologies. The recent discovery that glycogen synthase kinase-3 (GSK3) promotes …

LTP inhibits LTD in the hippocampus via regulation of GSK3β

S Peineau, C Taghibiglou, C Bradley, TP Wong, L Liu… - Neuron, 2007 - cell.com
Summary Glycogen synthase kinase-3 (GSK3) has been implicated in major neurological
disorders, but its role in normal neuronal function is largely unknown. Here we show that …

Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward

SM Arciniegas Ruiz, H Eldar-Finkelman - Frontiers in molecular …, 2022 - frontiersin.org
The protein kinase, GSK-3, participates in diverse biological processes and is now
recognized a promising drug discovery target in treating multiple pathological conditions …

Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder

CT Chiu, Z Wang, JG Hunsberger, DM Chuang… - Pharmacological …, 2013 - Elsevier
The mood stabilizers lithium and valproic acid (VPA) are traditionally used to treat bipolar
disorder (BD), a severe mental illness arising from complex interactions between genes and …

Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application

MJ Millan - Pharmacology & therapeutics, 2006 - Elsevier
Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

GSK-3 inhibitors: preclinical and clinical focus on CNS

H Eldar-Finkelman, A Martinez - Frontiers in molecular neuroscience, 2011 - frontiersin.org
Inhibiting glycogen synthase kinase-3 (GSK-3) activity via pharmacological intervention has
become an important strategy for treating neurodegenerative and psychiatric disorders. The …

Lithium and therapeutic targeting of GSK-3

ME Snitow, RS Bhansali, PS Klein - Cells, 2021 - mdpi.com
Lithium salts have been in the therapeutic toolbox for better or worse since the 19th century,
with purported benefit in gout, hangover, insomnia, and early suggestions that lithium …